Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(−) breast cancer that had progressed during or after prior endocrine therapy

BACKGROUND: Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor–positive (HR(+)), human epidermal growth factor receptor 2–negative (HER2(−)) breast cancer cases, is correlated with decreased overall survival and resistance to endocrine therapy (ET). Dovit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Breast Cancer Res
Asıl Yazarlar: Musolino, Antonino, Campone, Mario, Neven, Patrick, Denduluri, Neelima, Barrios, Carlos H., Cortes, Javier, Blackwell, Kimberly, Soliman, Hatem, Kahan, Zsuzsanna, Bonnefoi, Hervé, Squires, Matthew, Zhang, Yong, Deudon, Stephanie, Shi, Michael M., André, Fabrice
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5301372/
https://ncbi.nlm.nih.gov/pubmed/28183331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0807-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller